AMT intends to publish its full annual report on March 21, 2008.
Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and
expectations for future operations, prospects and financial condition.
Words such as "strategy," "expects," "plans," "anticipates," "believes,"
"will," "continues," "estimates," "intends," "projects," "goals," "targets"
and other words of similar meaning are intended to identify such
forward-looking statements. Such statements are based on the current
expectations of the management of Amsterdam Molecular Therapeutics only.
Undue reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be affected by
factors that are beyond the control of AMT. Actual results could differ
materially from current expectations due to a number of factors and
uncertainties affecting AMT's business, including, but not limited to, the
timely commencement and success of AMT's clinical trials and research
endeavors, delays in receiving U.S. Food and Drug Administration or other
regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's
products, effectiveness of AMT's marketing and sales efforts, development
of competing therapies and/or technologies, the terms of any future
strategic alliances, the need for additional capital, the inability to
obtain, or meet, conditions imposed for required governmental and
regulatory approvals and consents. AMT expressly disclaims any intent or
obligation to update these forward-looking statements except as require
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2008 PR Newswire.
All rights reserved